Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Quiescent complement in nonhuman primates during E coli Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy.

Lee BC, Mayer CL, Leibowitz CS, Stearns-Kurosawa DJ, Kurosawa S.

Blood. 2013 Aug 1;122(5):803-6. doi: 10.1182/blood-2013-03-490060. Epub 2013 Jun 3.

2.

Distinct renal pathology and a chemotactic phenotype after enterohemorrhagic Escherichia coli shiga toxins in non-human primate models of hemolytic uremic syndrome.

Stearns-Kurosawa DJ, Oh SY, Cherla RP, Lee MS, Tesh VL, Papin J, Henderson J, Kurosawa S.

Am J Pathol. 2013 Apr;182(4):1227-38. doi: 10.1016/j.ajpath.2012.12.026. Epub 2013 Feb 10.

3.

Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome.

Siegler RL, Obrig TG, Pysher TJ, Tesh VL, Denkers ND, Taylor FB.

Pediatr Nephrol. 2003 Feb;18(2):92-6. Epub 2003 Jan 10.

PMID:
12579394
4.

Role of complement in enterohemorrhagic Escherichia coli-Induced hemolytic uremic syndrome.

Orth-Höller D, Würzner R.

Semin Thromb Hemost. 2014 Jun;40(4):503-7. doi: 10.1055/s-0034-1375295. Epub 2014 May 5. Review.

PMID:
24799304
5.

Thrombotic microangiopathies.

Rosove MH.

Semin Arthritis Rheum. 2014 Jun;43(6):797-805. doi: 10.1016/j.semarthrit.2013.11.004. Epub 2013 Nov 16. Review.

PMID:
24360024
6.

Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.

Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, Rottoli D, Tedesco F, Remuzzi G, Zoja C.

J Immunol. 2011 Jul 1;187(1):172-80. doi: 10.4049/jimmunol.1100491. Epub 2011 Jun 3.

7.

Complement activation in diseases presenting with thrombotic microangiopathy.

Meri S.

Eur J Intern Med. 2013 Sep;24(6):496-502. doi: 10.1016/j.ejim.2013.05.009. Epub 2013 Jun 4. Review.

PMID:
23743117
8.

Interaction of Shiga toxin 2 with complement regulators of the factor H protein family.

Poolpol K, Orth-Höller D, Speth C, Zipfel PF, Skerka C, de Córdoba SR, Brockmeyer J, Bielaszewska M, Würzner R.

Mol Immunol. 2014 Mar;58(1):77-84. doi: 10.1016/j.molimm.2013.11.009. Epub 2013 Dec 5.

PMID:
24317278
9.

Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome.

Orth D, Khan AB, Naim A, Grif K, Brockmeyer J, Karch H, Joannidis M, Clark SJ, Day AJ, Fidanzi S, Stoiber H, Dierich MP, Zimmerhackl LB, Würzner R.

J Immunol. 2009 May 15;182(10):6394-400. doi: 10.4049/jimmunol.0900151.

10.

Complement in typical hemolytic uremic syndrome.

Orth D, Würzner R.

Semin Thromb Hemost. 2010 Sep;36(6):620-4. doi: 10.1055/s-0030-1262883. Epub 2010 Sep 23. Review.

PMID:
20865638
11.

Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome.

Arvidsson I, Ståhl AL, Hedström MM, Kristoffersson AC, Rylander C, Westman JS, Storry JR, Olsson ML, Karpman D.

J Immunol. 2015 Mar 1;194(5):2309-18. doi: 10.4049/jimmunol.1402470. Epub 2015 Jan 30.

PMID:
25637016
12.

Distinct physiologic and inflammatory responses elicited in baboons after challenge with Shiga toxin type 1 or 2 from enterohemorrhagic Escherichia coli.

Stearns-Kurosawa DJ, Collins V, Freeman S, Tesh VL, Kurosawa S.

Infect Immun. 2010 Jun;78(6):2497-504. doi: 10.1128/IAI.01435-09. Epub 2010 Mar 22.

13.

Thrombotic microangiopathies: from animal models to human disease and cure.

Caprioli J, Remuzzi G, Noris M.

Contrib Nephrol. 2011;169:337-50. doi: 10.1159/000314579. Epub 2011 Jan 20.

PMID:
21252531
14.

A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2.

Tremblay JM, Mukherjee J, Leysath CE, Debatis M, Ofori K, Baldwin K, Boucher C, Peters R, Beamer G, Sheoran A, Bedenice D, Tzipori S, Shoemaker CB.

Infect Immun. 2013 Dec;81(12):4592-603. doi: 10.1128/IAI.01033-13. Epub 2013 Sep 30.

15.

Pro-Coagulant Endothelial Dysfunction Results from EHEC Shiga Toxins and Host Damage-Associated Molecular Patterns.

Mayer CL, Parello CS, Lee BC, Itagaki K, Kurosawa S, Stearns-Kurosawa DJ.

Front Immunol. 2015 Apr 7;6:155. doi: 10.3389/fimmu.2015.00155. eCollection 2015.

16.

Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice.

Zoja C, Locatelli M, Pagani C, Corna D, Zanchi C, Isermann B, Remuzzi G, Conway EM, Noris M.

J Immunol. 2012 Oct 1;189(7):3661-8. Epub 2012 Aug 31.

17.

Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome.

Karpman D, Papadopoulou D, Nilsson K, Sjögren AC, Mikaelsson C, Lethagen S.

Blood. 2001 May 15;97(10):3100-8.

18.

[Hemolytic uremic syndrome in adults].

Hertig A, Ridel C, Rondeau E.

Nephrol Ther. 2010 Jul;6(4):258-71. doi: 10.1016/j.nephro.2010.03.002. Epub 2010 Apr 15. French.

PMID:
20399168
19.

Gnotobiotic piglets develop thrombotic microangiopathy after oral infection with enterohemorrhagic Escherichia coli.

Gunzer F, Hennig-Pauka I, Waldmann KH, Sandhoff R, Gröne HJ, Kreipe HH, Matussek A, Mengel M.

Am J Clin Pathol. 2002 Sep;118(3):364-75.

20.

Protection against Shiga toxin-producing Escherichia coli infection by transcutaneous immunization with Shiga toxin subunit B.

Zhu C, Yu J, Yang Z, Davis K, Rios H, Wang B, Glenn G, Boedeker EC.

Clin Vaccine Immunol. 2008 Feb;15(2):359-66. Epub 2007 Nov 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk